These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Local chemotherapy of malignant glioma. Intra-tumoral administration of neocarzinostatin]. Uemura S; Matsukado Y; Kuratsu J; Sonoda H; Ohtsuka T; Yoshioka S; Yamada M Neurol Med Chir (Tokyo); 1986 Jun; 26(6):468-74. PubMed ID: 2430207 [No Abstract] [Full Text] [Related]
24. [Bleomycin treatment of cancer of the penis]. Jorgensen SJ; Ohlsen AS; Andersen I Ugeskr Laeger; 1971 Feb; 133(8):345-8. PubMed ID: 5546965 [No Abstract] [Full Text] [Related]
25. [Toxic effects of cytostatic agents on the lung in monochemotherapy and polychemotherapy]. Renovanz HD Wien Med Wochenschr; 1983 Apr; 133(7):159-67. PubMed ID: 6868616 [No Abstract] [Full Text] [Related]
26. Side effects of the cytostatic agents Bleomycin and Peptichemio. Stacher A; Baumgartner G; Höcker P Int J Clin Pharmacol; 1973 Apr; 7(2):238-45. PubMed ID: 4125956 [No Abstract] [Full Text] [Related]
27. [Treatment of meningeal carcinomatosis--neocarzinostatin perfusion therapy in the CSF pathway]. Uemura S; Matsukado Y; Fujioka S; Kuratsu J; Sonoda H; Yano T; Ohtsuka T; Yoshioka S Gan To Kagaku Ryoho; 1985 Sep; 12(9):1794-800. PubMed ID: 2931051 [TBL] [Abstract][Full Text] [Related]
28. [Bleomycin. A preliminary report on a new antitumor antibiotic]. Rygård J; Hansen HS; Jensen KB; Aastrup J; Jorgensen SJ; Blichert-Toft M; Floystrup T; Gerlith A Ugeskr Laeger; 1971 Feb; 133(8):335-42. PubMed ID: 5546963 [No Abstract] [Full Text] [Related]
29. Neocarzinostatin: carboxyl-terminal-43-peptide residue of apo-neocarzinostatin as the binding site of neocarzinostatin-chromophore. Edo K; Saito K; Akiyama Y; Mizugaki M; Koide Y; Ishida N Chem Pharm Bull (Tokyo); 1986 Dec; 34(12):5180-3. PubMed ID: 2952300 [No Abstract] [Full Text] [Related]
30. [Neocarzinostatin therapy of advanced renal cell carcinoma]. Tari K; Satake I; Kojima S; Tsujii T; Yonese J Gan To Kagaku Ryoho; 1988 Sep; 15(9):2719-23. PubMed ID: 2970825 [TBL] [Abstract][Full Text] [Related]
31. [Reductive effect on ascites, of neocarzinostatin in patients with ovarian cancer]. Takahashi K; Watanabe M; Kikuchi J; Kishi H; Saito K; Mouri H; Ikeno N; Endo H; Shima I; Morizuka T Gan To Kagaku Ryoho; 1988 May; 15(5):1777-81. PubMed ID: 2967052 [TBL] [Abstract][Full Text] [Related]
32. [A case of complete remission following recurrent relapses 12 years after onset of acute myelocytic leukemia. Response to protocol including neocarzinostatin]. Odajima H; Iwatake K; Baba M; Ode S; Kawai H; Matsui T Gan To Kagaku Ryoho; 1988 Jan; 15(1):167-70. PubMed ID: 2962538 [TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of neocarzinostatin in digestive system cancer. 1. Administration of neocarzinostatin in advanced and recurrent carcinoma of the stomach]. Kikuchi K; Kusama S; Furue H; Muto T; Toriyama K; Wakiya M Gan To Kagaku Ryoho; 1983 Aug; 10(8):1866-71. PubMed ID: 6224465 [TBL] [Abstract][Full Text] [Related]
34. [Combination chemotherapy with neocarzinostatin (NCS) and other antitumor agents for advanced carcinoma of the digestive organs--improved clinical effect with NFO therapy]. Maeta M; Koga S; Shimizu N; Osaki Y; Hirai Y; Kato K; Masaki T; Maeta K; Kishimoto H; Watanabe S; Sugihara T; Iwasaki T; Tasaki M; Abe J; Yamashiro N Gan To Kagaku Ryoho; 1982 Oct; 9(10):1742-8. PubMed ID: 6223587 [TBL] [Abstract][Full Text] [Related]
36. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720 [TBL] [Abstract][Full Text] [Related]
37. [Pharmacokinetic one-compartment model using neocarzinostain as a prototype drug and its clinical application to chemotherapy for brain tumor. Part II. A clinical trial with selected protocol]. Matsukado Y; Maeda H; Uemura S; Kuratsu J; Sonoda H Gan To Kagaku Ryoho; 1982 Nov; 9(11):1933-41. PubMed ID: 6223589 [TBL] [Abstract][Full Text] [Related]
38. [Neocarzinostatin: molecular mechanism of action and prospects for clinical use]. Köhnlein W; Jung G Arzneimittelforschung; 1982; 32(11):1474-9. PubMed ID: 6217819 [TBL] [Abstract][Full Text] [Related]
39. [Clinical evaluation of neocarzinostatin in digestive system cancer. 2. Clinical studies on the administration of neocarzinostatin in advanced and recurrent carcinoma of the pancreas]. Kikuchi K; Kusama S; Furue H; Muto T; Toriyama K; Wakiya M Gan To Kagaku Ryoho; 1983 Aug; 10(8):1872-7. PubMed ID: 6224466 [TBL] [Abstract][Full Text] [Related]
40. [Postoperative adjuvant chemotherapy using NCS (neocarzinostatin) and 5-FU in the treatment of gastric cancer. First report--A comparison with the 5-year survival rate of patients undergoing combined therapy with MMC and 5-FU]. Yokomori T; Taniguchi T; Iesato H; Sakata Y; Watanabe T; Kawabe K Gan To Kagaku Ryoho; 1987 Nov; 14(11):3064-70. PubMed ID: 2960267 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]